A number of studies have implicated a role for the cell surface glycoprotein CD44 in several biologic events, such as lymphopoiesis, homing, lymphocyte activation, and apoptosis. We have earlier reported that signaling via CD44 on naive B cells in addition to B-cell receptor (BCR) and CD40 engagement generated a germinal center–like phenotype. To further characterize the global role of CD44 in B differentiation, we examined the expression profile of human B cells cultured in vitro in the presence or absence of CD44 ligation, together with anti-immunoglobulin (anti-Ig) and anti-CD40 antibodies. The data sets derived from DNA microarrays were analyzed using a novel statistical analysis scheme created to retrieve the most likely expression pattern of CD44 ligation. Our results show that genes such as interleukin-6 (IL-6), IL-1α, and β2-adrenergic receptor (β2-AR) were specifically up-regulated by CD44 ligation, suggesting a novel role for CD44 in immunoregulation and inflammation.

B-cell differentiation is highly regulated by components in the surrounding microenvironment1 and is a central process in the humoral immune response. This often involves germinal center reactions eventually leading to population of the memory compartment as well as to generation of plasma cells.2 Important players in this process are, for example, adhesion molecules from the families of integrins, selectins, and immunoglobulins, as well as chemoattractants, such as the chemokines.3 

The cell surface glycoprotein CD44 is a member of the hyaladherin or link protein superfamily (LPSF) that interacts with the polysaccharide hyaluronan (HA) in the extracellular matrix (ECM). It is widely distributed in the body and mediates cell-cell and cell-matrix interactions. In the hematopoietic system CD44 is expressed on all cell types and has been shown to play a role in lymphopoiesis and lymphocyte homing4 as well as in lymphocyte activation5,6 and apoptosis.6,7 CD44 has furthermore been associated with several different pathologic states where the linkage to cancer and autoimmune diseases is the most notable.4 8 

All mechanisms supporting B-cell differentiation from a mature naive B cell to an immunoglobulin (Ig)–producing plasma cell are still not entirely understood, although many components have been identified.2 We and others have previously investigated the role of CD44 in the regulation of T-cell–dependent B-cell activation9 and subsequent germinal center formation,10 where ligation of CD44 was shown to contribute to the induction of a phenotype closely resembling a germinal center (GC) B cell.

B cells up-regulate CD44 upon activation,9,11,12 and HA-CD44 interactions induce activation of mature B cells in vivo.5 However, CD44 is down-regulated during the germinal center reaction.13-15 Interestingly, ectopic GC-like structures are found in several autoimmune and inflammatory diseases,16,17 indicating that a microenvironment promoting formation of GC-like follicular structures is generated in these pathologic states. Apart from T cells and follicular dendritic cells at these GC-like structures,18,19 an increase in expression levels of CD44 was evident.20 21 

To further elucidate the functional effects of CD44 ligation on B cells, we assessed the transcriptional profiles from anti-CD44-stimulated naive B cells also costimulated via CD40 and the B-cell receptor (BCR). The transcriptional profile of approximately 6800 genes was evaluated by using a high-density DNA microarray technique. To facilitate the analysis of the complex patterns in the data set, we developed a novel statistical analysis scheme that accounts for inherent errors in the experimental handling and process often seen in these types of studies.22 23 In summary, the CD44-dependent regulated genes in our analysis were found to mainly pertain to proteins involved in inflammation and immunomodulation. Interestingly, the expression patterns regulated by CD44 fall into 2 groups: (1) genes augmented or repressed by CD44 in a temporal fashion and (2) genes directly regulated—that is, induced—by CD44 alone. Our results suggest a role for CD44 in the modulation of the mature B-cell response and may also have implications in inflammatory and autoimmune diseases, because genes such as the β2-adrenergic receptor for norepinephrin, platelet-derived endothelial cell growth factor, as well as interleukin-6 (IL-6) and IL-1α were induced by CD44.

Antibodies

R-phycoerythrin (RPE)–conjugated anti-CD38 antibodies were obtained from Biosciences (BD; San Jose, CA). Anti-IgD-fluorescein isothiocyanate (FITC) and anti-CD3–phycoerythrin (PECy5) was obtained from Dako (Glostrup, Denmark), and anti-CD38-PECy5 antibody was purchased from PharMingen (San Diego, CA). Mouse antihuman IgM (AF6) and mouse antihuman CD44 (BU52) antibodies were kindly provided by I. MacLennan (University of Birmingham, United Kingdom). Mouse antihuman CD40 (S2C6) was a gift from S. Pauli (Stockholm University, Sweden).

Cells

Human tonsils were obtained from 4 different pediatric patients undergoing routine tonsillectomy at the University Hospitals of Lund or Malmö. Briefly, tonsils were minced and T cells were removed by rosetting with neuraminidase-treated sheep red blood cells. Mononuclear T-cell–depleted cells were isolated by density centrifugation using Ficoll-Isopaque (Amersham Pharmacia Biotech, Uppsala, Sweden). The interphase fraction, containing predominantly B cells, was washed in phosphate-buffered saline (PBS) containing fetal bovine serum (FBS) (10%) and incubated with precoated anti-CD38 Dynabeads, sheep antimouse IgG, or pan-mouse IgG (Dynal Biotech, Oslo, Norway) for 45 minutes on ice. Cells depleted for CD38 were stained with anti-CD38-PECy5, anti-CD3-PECy5, and anti-IgD-FITC antibodies. Positive selection using flow cytometric cell sorting of IgD+/CD38 B cells to a purity exceeding 98% was performed on a FACS Vantage SE cell sorter (BD).

Cell culture condition

IgD+/CD38 B cells (2.0 × 106) from the 4 different human donors were separately cultured at 37°C, 5% CO2, for a total of 6 hours, 24 hours, and 72 hours on 1.5 × 105CD32-transfected fibroblasts (162CG7) with 0.2 μg/mL anti-IgM (AF6) and 1.0 μg/mL anti-CD40 (S2C6) antibodies, with or without 1.0 μg/mL anti-CD44 (BU52) antibodies. The culture was performed in flat-bottomed 24-well plates (Costar, Corning, NY) using complete medium: RPMI 1640 supplemented with 2 mM l-glutamine, 1% nonessential amino acids, 50 μg/mL gentamicin (Gibco Life Technologies, Gaithersburg, MD), and 10% FBS (Hyclone Laboratories, Logan, UT).

Isolation of mRNA

Freshly isolated cells from each separate culture were lysed in Trizol (Life Technologies). The RNA was extracted from the cell lysate by adding 0.2 vol chloroform. The aqueous phase containing the RNA was separated and subsequently precipitated with isopropanol and washed in 75% ethanol. The RNA pellet was dissolved in diethylene pyrocarbonate (DEPC)-treated water and further purified with the RNeasy Mini Kit (QIAGEN, Hilden, Germany). The total RNA content was assessed spectrophotometrically (GeneQuant II, Amersham, Pharmacia Biotech) within a 260/280 nm OD (optic density) ratio of 1.9:2.1. After a second precipitation step in 2.5 vol ethanol and subsequent wash, the RNA was resuspended in DEPC-treated water. Five micrograms of total RNA was used for the cDNA and cRNA synthesis, as previously described24; cRNA is quality controlled by gel electrophoresis.

Hybridization and scanning of the DNA chips

A hybridization cocktail was prepared with the biotinylated and fragmented cRNA at 50 μg/mL, as described previously,24and hybridized onto HuGeneFL microarrays (Affymetrix, Santa Clara, CA). The probe array was then stained with a solution of 2 mg/mL acetylated bovine serum albumin (BSA) and 10 μg/mL streptavidin R-phycoerythrin (Molecular Probes, Eugene, OR). A secondary stain was performed with acetylated BSA, normal goat IgG (Sigma Chemical, St Louis, MO), and biotinylated goat antistreptavidin antibody (Vector Laboratories, Burlingame, CA) for amplification. A final staining step with streptavidin R-phycoerythrin was performed before the probe arrays were scanned in the gene array scanner and checked using the Micro Array Suite 4.0 (Affymetrix), as described previously.24 Several controls assessing the overall processing, the hybridization, and the quality of the material are included on the microarray. A total of 6 arrays were run for every donor, one for every time point for both the anti-CD44–stimulated and nonstimulated cells. In total, 24 arrays were evaluated.

Statistical analysis

A brief review of the mathematical details of the statistical data analysis is given here, and a more detailed description is available elsewhere (S.B., T.B., and M. Sigvardsson, unpublished data, 2002). The data consist of 6 different biologic varieties: anti-CD44-treated cells at 6, 24, and 72 hours after the onset of treatment and untreated cells sampled at the same time points. Each variety consists of 4 samples—that is, from the 4 different human donors. For each variety, data are discretized using the Affymetrix “present/absent” calls so that each gene is represented by a vector S ∈ {0,1}4. The distribution of observed states S in the variety is assumed to be generated by 3 underlying biologic states: ς0 for expression below the detection level of the chips, ς1 for expression above detection level, and ςT for genes with varying expression levels in the 4 samples. The latter state is assumed to give rise to random vectors S with equal probabilities of 0 or 1 at each position. For each measurement, a certain noise characteristic is assumed. This noise characteristic is modeled by misclassification probabilities {P01iP10i}i=14.

To simplify the notation, we introduce the S dependent variables:

The distribution of observed states S is then modeled by

This distribution is fitted to the observed data by χ2 minimization of the unweighted errors. With the parameter estimates generated from the fit, we may now calculate the belief in terms of probability for an underlying state given the observed one. P(ς¦S) = [P(S¦ς)P(ς)]/P(S) whereς ∈ {ς0,ςT,ς1}. For the 36 = 729 possible expression profiles over the whole set of varieties υ ∈ {6h+, 24h+, 72h+, 6h−, 24h−, 72h−}, we calculate the probability of each one of them by Π P(ςυ ¦ Sυ).

For simplicity, the underlying states ς0,ςT, and ς1 are throughout the paper referred to by their index symbols 0, T, and 1. Further, the expression profile of a gene over the 6 varieties will be denoted, for example, 0T1000, where the position of 0, T, or 1 in this pattern refers to the expressional state in the variety 6h+, 24h+, 72h+, 6h−, 24h−, 72h−, respectively.

Flow cytometry and ELISA

Freshly isolated cells from each separate culture were assayed for IL-1α surface expression by flow cytometry using a FACScan (BD) and for IL-6 expression in the supernatant using enzyme-linked immunosorbent assay (ELISA). Anti-IL-1α-PE was purchased from PharMingen, while the human IL-6 ELISA kit was purchased from R&D Systems (Minneapolis, MN).

To study the transcriptional changes associated with a CD44 stimuli on naive B cells, the entire cell population from ectomized pediatric tonsils was fractionated and a naive B-cell subset, defined by immunoglobulin (Ig) D cell surface expression and a lack of CD38, was collected. These cells were propagated in the presence of anti-CD40 and anti-IgM antibodies and immobilized on CD32-transfected fibroblasts.25 The phenotypic and functional changes then attributed to a CD44 stimulation were evaluated at 6, 24, and 72 hours over 4 separate samples using high-density DNA microarrays displaying probes for approximately 6800 genes and several hundred expressed sequence tags (ESTs).

To investigate the sample coherence, we constructed a Hamming distance matrix of all samples (Figure 1). This validation clearly shows how samples labeled 1 in both treated and untreated cells at 72 hours deviate from the other samples. The deviation is also noted as raised misclassification probabilities for these samples (data not shown). Because the algorithm is designed to handle deviations even of this magnitude, the samples were retained.

Fig. 1.

Hamming distance matrix visualizing the number of genes differing between any 2 samples.

The color scale ranges from black, indicating no difference, to white, indicating a 2828-gene difference. The ordering is as follows (from the lower left corner up and right): CD44-stimulated (indicated as +CD44) sample no. 1 at 6, 24, and 72 hours; CD44-stimulated sample no. 2, at 6, 24, and 72 hours; sample no. 3 at 6, 24, and 72 hours; and sample no. 4 at 6, 24, and 72 hours. In a corresponding series is the control receiving no CD44 stimuli (indicated -CD44).

Fig. 1.

Hamming distance matrix visualizing the number of genes differing between any 2 samples.

The color scale ranges from black, indicating no difference, to white, indicating a 2828-gene difference. The ordering is as follows (from the lower left corner up and right): CD44-stimulated (indicated as +CD44) sample no. 1 at 6, 24, and 72 hours; CD44-stimulated sample no. 2, at 6, 24, and 72 hours; sample no. 3 at 6, 24, and 72 hours; and sample no. 4 at 6, 24, and 72 hours. In a corresponding series is the control receiving no CD44 stimuli (indicated -CD44).

Close modal

To assess the difference in gene expression induced by CD44 ligation, the genes were clustered according to their most probable expression profile over the 6 varieties. These expression profiles can be viewed as 6-letter strings composed by 0, T, or 1 in the following order: 6h+, 24h+, 72h+, 6h−, 24h−, 72h−. For example, a gene with most probable expression profile 01T000 is below the detection level of the chip at 6 hours in the treated group, above the detection level at 24 hours in the treated group, and transient (varying) in the treated group at 72 hours. However, the expression level is below the detection level at all times in the untreated group.

To select genes directly regulated by CD44 (ie, induced or repressed by CD44) at all times, we extracted those having an expression pattern matching (1/T, 1/T, 1/T, 0, 0, 0) and (0, 0, 0, 1/T, 1/T, 1/T). To select temporally regulated genes (ie, genes having an earlier or delayed induction by CD44), we extracted those having an expression pattern matching (1/T, 1/T/0, 1/T/0, 0, 1/T/0, 1/T/0) and (0, 1/T/0, 1/T/0, 1/T, 1/T/0, 1/T/0). The selected clusters were further refined by applying a ranking of the genes having the highest appearance frequency within each specific pattern. In this way the most significant members were assessed. Tables1 and2 show genes directly regulated by CD44, and Tables 3 and4 show genes temporally regulated by CD44.

Table 1.

Genes directly regulated and induced by anti-CD44

HGNC*AnnotationAccession no.Pattern
IL1A Interleukin 1, alpha M28983 TTT000 
NA Human clone 23908 mRNA sequence U79290 TTT000  
NA Human (BSF-2/IL6) gene for B cell stimulatory factor-2 Y00081 TTT000 
PDE6A Phosphodiesterase 6A, alpha subunit M26061 TT1000  
NA H sapiens mRNA sequence (15q11-13) X69636 TT0000 
C18B11 C18B11 homolog U67934 TT0000 
MLLT3 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3 L13744 T1T000  
SOX5 SRY (sex-determining region Y)-box 5 S83308 T10000 
ATP1A2 ATPase, Na+K+ transporting, alpha-2 polypeptide J05096 T10000 
AQP1 Aquaporin 1 U41518 T0T000 
STX1A Syntaxin 1A L37792 T0T000 
PLG Plasminogen M34276 T01000 
IF I factor Y00318 T00000 
AFAP Actin filament associated protein D25248 1TT000  
SH3BP2 SH3-domain binding protein 2 AB000462 11T000 
GCNT2 Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme L41607 0TT000 
PYGL Phosphorylase, glycogen; liver M14636 0TT000  
ADRB2 Adrenergic, beta-2-, receptor, surface M15169 0TT000 
PIGA Phosphatidylinositol glycan, class A S78467 0TT000  
ECGF1 Endothelial cell growth factor 1 S72487 0T1000 
NBL1 Neuroblastoma, suppression of tumorigenicity 1 D28124 0T1000 
MITF Microphthalmia-associated transcription factor Z29678 0T0000  
STK9 Serine/threonine kinase 9 X89059 00T000 
ALB Albumin U22961 00T000 
CAMK2D Calcium/calmodulin-dependent protein kinase (CaM kinase) II delta U50361 00T000 
MAPK14 Mitogen-activated protein kinase 14 L35253 00T000  
RGS3 Regulator of G-protein signaling 3 U27655 00T000 
SERPINC1 Serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1 M21642 00T000 
HGNC*AnnotationAccession no.Pattern
IL1A Interleukin 1, alpha M28983 TTT000 
NA Human clone 23908 mRNA sequence U79290 TTT000  
NA Human (BSF-2/IL6) gene for B cell stimulatory factor-2 Y00081 TTT000 
PDE6A Phosphodiesterase 6A, alpha subunit M26061 TT1000  
NA H sapiens mRNA sequence (15q11-13) X69636 TT0000 
C18B11 C18B11 homolog U67934 TT0000 
MLLT3 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3 L13744 T1T000  
SOX5 SRY (sex-determining region Y)-box 5 S83308 T10000 
ATP1A2 ATPase, Na+K+ transporting, alpha-2 polypeptide J05096 T10000 
AQP1 Aquaporin 1 U41518 T0T000 
STX1A Syntaxin 1A L37792 T0T000 
PLG Plasminogen M34276 T01000 
IF I factor Y00318 T00000 
AFAP Actin filament associated protein D25248 1TT000  
SH3BP2 SH3-domain binding protein 2 AB000462 11T000 
GCNT2 Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme L41607 0TT000 
PYGL Phosphorylase, glycogen; liver M14636 0TT000  
ADRB2 Adrenergic, beta-2-, receptor, surface M15169 0TT000 
PIGA Phosphatidylinositol glycan, class A S78467 0TT000  
ECGF1 Endothelial cell growth factor 1 S72487 0T1000 
NBL1 Neuroblastoma, suppression of tumorigenicity 1 D28124 0T1000 
MITF Microphthalmia-associated transcription factor Z29678 0T0000  
STK9 Serine/threonine kinase 9 X89059 00T000 
ALB Albumin U22961 00T000 
CAMK2D Calcium/calmodulin-dependent protein kinase (CaM kinase) II delta U50361 00T000 
MAPK14 Mitogen-activated protein kinase 14 L35253 00T000  
RGS3 Regulator of G-protein signaling 3 U27655 00T000 
SERPINC1 Serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1 M21642 00T000 
*

Annotation based on HUGO Gene Nomenclature Committee (HGNC):http://www.gene.ucl.ac.uk/nomenclature/.

NA indicates not applicable.

Table 2.

Genes directly regulated and repressed by anti-CD44

HGNC*AnnotationAccession no.Pattern
SSTR4 Somatostatin receptor 4 L14856 000TTT 
NA H sapiens CREB gene X68994 000TTT 
PALM Paralemmin D87460 000TT0 
NA H sapiens mRNA for NK receptor X97230 000TT0  
SLC14A1 Solute carrier family 14 member 1 U35735 000T0T 
PRDM2 PR domain containing 2 U17838 000T0T 
HLCS Holocarboxylase synthetase D87328 000T01  
APC Adenomatosis polyposis coli M73548 000T00 
MLLT10 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10 U13948 0001T0  
PLS1 Plastin 1 L20826 0000TT  
LU Lutheran blood group X80026 0000TT  
SERPINA1 Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 K01396 0000T0 
LAMP2 Lysosomal-associated membrane protein 2 L09717 0000T0  
GUCY2F Guanylate cyclase 2F, Retinal L37378 00000T 
EPHB3 EphB3 X75208 00000T 
HGNC*AnnotationAccession no.Pattern
SSTR4 Somatostatin receptor 4 L14856 000TTT 
NA H sapiens CREB gene X68994 000TTT 
PALM Paralemmin D87460 000TT0 
NA H sapiens mRNA for NK receptor X97230 000TT0  
SLC14A1 Solute carrier family 14 member 1 U35735 000T0T 
PRDM2 PR domain containing 2 U17838 000T0T 
HLCS Holocarboxylase synthetase D87328 000T01  
APC Adenomatosis polyposis coli M73548 000T00 
MLLT10 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10 U13948 0001T0  
PLS1 Plastin 1 L20826 0000TT  
LU Lutheran blood group X80026 0000TT  
SERPINA1 Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 K01396 0000T0 
LAMP2 Lysosomal-associated membrane protein 2 L09717 0000T0  
GUCY2F Guanylate cyclase 2F, Retinal L37378 00000T 
EPHB3 EphB3 X75208 00000T 
*

Annotation based on HUGO Gene Nomenclature Committee (HGNC):http://www.gene.ucl.ac.uk/nomenclature/.

NA indicates not applicable.

Table 3.

Genes temporally regulated by induction by CD44

HGNC3-150AnnotationAccession no.Pattern
PRPF18 PRP18 pre-mRNA processing factor 18 U51990 1TT00T 
NFKB2 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 U20816 1T10TT 
KDELR1 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 X55885 1T10TT 
PNMT PhenylethanolamineN-methyltransferase X52730 1T10T1 
DDX7 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 7 (RNA helicase, 52 kDa) D26528 1T100T 
MME Membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10) J03779 11T0TT 
MPP3 Membrane protein, palmitoylated 3 U37707 11T0T1  
KIAA0121 KIAA0121 gene product D50911 1110T1  
TNFRSF6 Tumor necrosis factor receptor superfamily, member 6 X63717 11101T  
NA Human XIST X56199 111011  
DIPA Hepatitis delta antigen-interacting protein A U63825 111011 
PRIM2 Primase, polypeptide 2A X74331 111011 
GPR31 G protein-coupled receptor 31 U65402 10T0T0  
HR44 Hr44 antigen X91103 10T0T0 
HGNC3-150AnnotationAccession no.Pattern
PRPF18 PRP18 pre-mRNA processing factor 18 U51990 1TT00T 
NFKB2 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 U20816 1T10TT 
KDELR1 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 X55885 1T10TT 
PNMT PhenylethanolamineN-methyltransferase X52730 1T10T1 
DDX7 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 7 (RNA helicase, 52 kDa) D26528 1T100T 
MME Membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10) J03779 11T0TT 
MPP3 Membrane protein, palmitoylated 3 U37707 11T0T1  
KIAA0121 KIAA0121 gene product D50911 1110T1  
TNFRSF6 Tumor necrosis factor receptor superfamily, member 6 X63717 11101T  
NA Human XIST X56199 111011  
DIPA Hepatitis delta antigen-interacting protein A U63825 111011 
PRIM2 Primase, polypeptide 2A X74331 111011 
GPR31 G protein-coupled receptor 31 U65402 10T0T0  
HR44 Hr44 antigen X91103 10T0T0 
F3-150

Annotation based on HUGO Gene Nomenclature Committee (HGNC):http://www.gene.ucl.ac.uk/nomenclature/.

NA indicates not applicable.

Table 4.

Genes temporally regulated by repression by CD44

HGNC4-150AnnotationAccession no.Pattern
KIAA0196 KIAA0196 gene product D83780 00T1TT 
CRYGEP1 Crystallin, gamma E pseudogene 1 K03008 00T1TT 
LYZ Lysozyme J03801 00T1TT 
KIAA0141 KIAA0141 gene product D50931 00TT0T  
TERF1 Telomeric repeat binding factor U40705 00TT1T 
EFNA3 Ephrin-A3 U14187 00TTT0 
RNTRE Related to the N terminus of tre D13644 00TTT1  
NUCB2 Nucleobindin 2 X76732 00TTT1  
PAFAH2 Platelet-activating factor acetylhydrolase 2 D87845 00TTTT 
GCG Glucagon J04040 00TTTT 
ELL ELL gene U16282 00TTTT 
MNAT1 Menage a trois 1 (CAK assembly factor) X87843 00TTTT  
NR4A3 Nuclear receptor subfamily 4, group A, member 3 X89894 01T1TT 
SLC18A1 Solute carrier family 18, member 1 U39905 0T0TTT  
NA Human clone 23907 mRNA sequence U90907 0T111T  
PLK Pololike kinase U01038 0T1T11  
CCNG2 Cyclin G2 U47414 0T1T11  
MX2 Myxovirus (influenza virus) resistance 2 M30818 0T1T1T 
HTR1A 5-hydroxytryptamine (serotonin) receptor 1A M83181 0TT11T  
FRDA Friedreich ataxia U43747 0TT11T  
MEF2A MADS box transcription enhancer factor 2, polypeptide A X68505 0TT1T1  
SNCA Synuclein, alpha U46901 0TTT11  
APOC3 Apolipoprotein C-III X01388 0TTT1T  
PRKACA Protein kinase, cAMP-dependent, catalytic, alpha M80335 0TTTT1 
AUH AU RNA binding protein/enoyl-coenzyme A hydratase X79888 0TTTT1 
HGNC4-150AnnotationAccession no.Pattern
KIAA0196 KIAA0196 gene product D83780 00T1TT 
CRYGEP1 Crystallin, gamma E pseudogene 1 K03008 00T1TT 
LYZ Lysozyme J03801 00T1TT 
KIAA0141 KIAA0141 gene product D50931 00TT0T  
TERF1 Telomeric repeat binding factor U40705 00TT1T 
EFNA3 Ephrin-A3 U14187 00TTT0 
RNTRE Related to the N terminus of tre D13644 00TTT1  
NUCB2 Nucleobindin 2 X76732 00TTT1  
PAFAH2 Platelet-activating factor acetylhydrolase 2 D87845 00TTTT 
GCG Glucagon J04040 00TTTT 
ELL ELL gene U16282 00TTTT 
MNAT1 Menage a trois 1 (CAK assembly factor) X87843 00TTTT  
NR4A3 Nuclear receptor subfamily 4, group A, member 3 X89894 01T1TT 
SLC18A1 Solute carrier family 18, member 1 U39905 0T0TTT  
NA Human clone 23907 mRNA sequence U90907 0T111T  
PLK Pololike kinase U01038 0T1T11  
CCNG2 Cyclin G2 U47414 0T1T11  
MX2 Myxovirus (influenza virus) resistance 2 M30818 0T1T1T 
HTR1A 5-hydroxytryptamine (serotonin) receptor 1A M83181 0TT11T  
FRDA Friedreich ataxia U43747 0TT11T  
MEF2A MADS box transcription enhancer factor 2, polypeptide A X68505 0TT1T1  
SNCA Synuclein, alpha U46901 0TTT11  
APOC3 Apolipoprotein C-III X01388 0TTT1T  
PRKACA Protein kinase, cAMP-dependent, catalytic, alpha M80335 0TTTT1 
AUH AU RNA binding protein/enoyl-coenzyme A hydratase X79888 0TTTT1 
F4-150

Annotation based on HUGO Gene Nomenclature Committee (HGNC):http://www.gene.ucl.ac.uk/nomenclature/.

NA indicates not applicable.

The ligation of CD44 on a naive B-cell population was recently shown by us to partially induce a germinal center phenotype,10 as defined by an up-regulation of CD10, CD77, and CD95. The present analysis confirmed the induced presence of CD10 (MME) and CD95 (TNFRSF6) on the transcriptional level (Table 2). The neutral glycosphingolipid CD77 is not represented on the microarray. In the present setting the difference in CD10 and CD95 expression was attributed to a temporal induction, because the CD95 transcript was found in the 11101T cluster and the CD10 is found in the 11T0TT cluster. This indicated that CD44-dependent induction of these molecules occurred at the earlier time points.

The list of directly regulated genes represents several novel members. In the cluster designated 00T000, representing genes differentially expressed at 72 hours by CD44 ligation, is the SERPINC1 transcript for antithrombin III found. This cluster also contains the RGS3 transcript for the G-protein signaling regulator 3 protein, which is involved in the regulation of chemoattractant-mediated migration in lymphocytes.26,27 The cluster 0TT000, representing genes that are differentially up-regulated after 6 hours by the CD44 ligation, contains the transcript for the β2-adrenergic receptor (ADRB2). This receptor binds the sympathetic nervous system (SNS) mediator norepinephrine. This is of interest, because norepinephrine innervation of lymphoid organs plays a central regulatory role in the immune system.28 

In the cluster 0T1000 we found the platelet-derived endothelial cell growth factor (ECGF1). This cytokine is known for its involvement in cancer and rheumatoid arthritis and has, for instance, been shown to induce inflammation and hyperplasia in synovial cells.29In the cluster described by TTT000, the immunomodulating interleukins IL-6 and IL-1α (IL1A) were found. IL-6 is secreted upon inflammation and has a wide array of functions both centrally and peripherally.30 IL-1α is another cytokine that has been implicated in functions both centrally and peripherally. In this context, it is a cytokine that has been considered to have overlapping functions with IL-1β,31 although IL-1α has been found not to compensate for IL-1β loss.32 However, several studies have reported a role for IL-1α in T helper cell regulation,33,34 suggesting a more confined functionality.

The up-regulation of IL-1α and IL-6 mRNA led us to investigate their presence at the protein level. Flow cytometry analysis was used to detect surface expression of IL-1α at the various time points after CD44 ligation. The population of IL-1α-expressing cells increased by a factor of 3.9 (SEM 0.44) at 24 hours. In total, 10% (SEM 0.16) of the total CD44-stimulated B-cell population was IL-1α+ at 24 hours (data not shown). The IL-6 production at the various time points after CD44 ligation was assessed by ELISA. The average net increase of CD44-induced IL-6, observed at 24 and 72 hours, was 1.6 times (SEM 0.26), reaching a total concentration of 300 pg/mL (SEM 30.0). These findings validate the CD44 involvement in the induction of these 2 immunomodulatory cytokines.

The hyaluronan (HA) receptor CD44 has been implicated in the regulation of the immune system, and as a member of the hyaladherin family of proteins its role in adhesion and extracellular interactions has been extensively investigated.4 Furthermore, a crucial role of CD44 in inflammation has also lately been demonstrated.35 In the present study we assessed the transcriptional outcome of ligation of CD44 on mature naive tonsillar B cells. The dataset was analyzed employing a novel statistical analysis scheme created to retrieve the most likely expression pattern of an observed distribution. We were thus able to extract the patterns for genes classified as directly or temporally regulated by the anti-CD44 stimuli (Tables 1-2).

Our previous observation that CD44 ligation in naive B cells in fact induced a GC B-cell–like phenotype was corroborated in the present transcriptional analysis, in that CD10 (MME) and CD95 (TNFRSF6) were shown to be temporally regulated by CD44. The neutral endopeptidase CD10 has a strong association to activated germinal center B-cell populations,36 and the only other stage in B-cell ontogeny where CD10 is expressed is at the pro-B-cell stage in bone marrow. The functional role of CD10 is associated to inflammation, and CD10 provides protection to several neuropeptides and other mediators of inflammation in tissue. Some of the substrates include endothelin, bradykinin, substance P, calcitonin gene-related peptide, neuropeptide Y, and IL-1β.37 The CD95 expression is also highly associated with activation, especially in lymphocytes.38This receptor is a prerequisite for a physiological control of the activated immune system, enabling the possibility to clear malfunctioning cells by apoptosis. If this control is perturbed, the imbalance in the immune system could lead to autoimmunity. Interestingly, an increased susceptibility to CD95-mediated activation-induced cell death has been linked to CD44 functionality on thymocytes.6 7 

Among the components that were found to be directly regulated by CD44 were the cytokines IL-6 and IL-1α. IL-6 is a pleiotropic molecule involved as a regulator of inflammation both centrally and peripherally.30 A role of IL-6 in the induction and progression of arthritis has also been demonstrated in IL-6–deficient mice.39 IL-6–deficient mice, furthermore, show impaired antibody production and reduced numbers of both B and T cells in lymph nodes as well as reduced germinal center formation.40 The induction of IL-6 is not unique to CD44, because IL-6 induction has been associated also with CD40-mediated signaling.41However, CD44 has been shown to augment IL-6 production in human rheumatoid synovial cells42 and polymorphonuclear cells,43 which is in agreement with our findings where the CD44 ligation generated an increase in IL-6 protein production. Interestingly, it has also recently been reported that IL-6 production can be specifically attributed to CD44 v6 at least in macrophages.44 

Direct regulation by the CD44 stimuli was evident also for the IL-1α transcript (IL1A). This induction seems to be present relatively early in time and is sustained throughout the 72 hours as it follows the TTT000 pattern. Several studies have demonstrated a CD44-dependent induction of IL-1.45,46 However, in contrast to previous studies, the CD44 ligation on the BCR and CD40-activated B cells induced IL-1α. The immunomodulatory function of IL-1α is mostly associated with T helper cell proliferation. It induces T helper-2 (TH2) cell proliferation independently of IL-4 and initiates autocrine IL-1α production,34 which furthermore has been shown to increase the TH2 responsiveness to IL-4.47 Our confirmation that IL-1α was up-regulated at the protein level also demonstrated that a CD44 ligation augmented this surface expression, and a nearly 4-fold increase in the number of IL-1α–producing cells was evident. Taken together, these results suggest an attractive role of CD44-activated B cells in the regulation of T-cell proliferation.

CD44 has also been implicated in lymphocyte migration. In this study SERPINC1 and RSG3, both potent regulators of migration, were shown to be regulated by CD44. The serpin, antithrombin III (SERPINC1), is an important regulator of the coagulation cascade as well as being involved in inflammation.48 Antithrombin III has also been found to inhibit chemokine-mediated migration through the heparan sulfate proteoglycans syndecan-4 49 and by a similar interaction also to interfere with nuclear factor-κB (NF-κB) activation,50 which explains the anti-inflammatory effects of the enzyme. Another regulator of chemokine-mediated migration with a differential expression pattern is the G-protein signaling regulator RGS3. This molecule is a modulator of chemotaxis and cell adhesion mediated by G protein-coupled chemokine receptors26 and has been found to efficiently inhibit B-cell chemotaxis mediated by the CXCR4, CXCR5, and CCR7.27 Thus, the regulatory properties of SERPINC1 and RSG3 may be of critical importance, because a balance in the chemokine-mediated migration of lymphocytes has shown to be instructive in the formation of the secondary lymphoid organ structures.3 

Another up-regulated immunoregulatory gene dependent on CD44 stimulation is the β2-adrenergic receptor (β2-AR). The adaptive response to inflammation involves components of the central nervous system (CNS). The systemic release of proinflammatory cytokines triggers the enrollment by CNS of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS). These systems in concert modulate the immune response by a subsequent release of glucocorticoids from the adrenal glands and norepinephrine (NE) by postganglionic noradrenergic nerve endings, respectively. The peripheral discharge of glucocorticoids and NE will inhibit TH1 responses and promote a TH2 response thereby counteracting the inflammatory reaction.43,51,52 The sympathetic regulation of the immune system is mediated mainly by the β2-AR, which has been found on all lymphocytes except for TH2 cells. In B cells it has been reported that the β2-AR facilitates TH2-dependent IgG1 and IgE production quantitatively after antigen stimulation in mice.53,54 It is also proposed that the β2-AR plays a role in germinal center formation, because NE depletion attenuates GC formation.53 The β2-AR transcript ADRB2 is contained in a cluster characterizing genes induced after 24 hours (0TT000). This indicates that in line with proinflammatory cytokines55 the CD44 stimuli seem to be a regulator of the β2-AR expression of B cells. The β2-adrenergic receptor uses the cyclic adenosine monophosphate (cAMP) and the protein kinase A (PKA) pathway. This pathway has been reported to regulate TH1 and TH2 responses and TH2-dependent IgE and IgG production in B cells by a number of effectors.56 Thus, the induced presence of the β2-AR suggests a B cell involved in a TH2-dependent response.

Interestingly, a recent study demonstrated rapid down-regulation of CD44 on NK cells by NE treatment,57 and it is possible to speculate on a similar mechanism in the heavily innervated marginal zone. Such a mechanism presents a possible scenario where the CD44 participates in the decision making of the B-cell faith. For example, antigen-induced CD44 9,11,12 will as a costimultory molecule9 participate in a T cell-B cell cognate interaction with a sequential up-regulation of the β2-AR. This β2-AR up-regulation will mount the pivot point in this regulatory process at which the neuroendocrine system decides whether a germinal center formation should be supported or not. The β2-AR signaling will consequently induce cellular events facilitating GC formation53 54 characterized by a CD44 down-regulation.

In summary, our results suggest a novel role for CD44 in immunoregulation and inflammation. More specifically, possible mechanisms for CD44 involvement in the humoral response and the formation of germinal center reactions based on the up-regulation of transcript for CD10, CD95, IL-6, IL-1α, and β2-AR are proposed.

Prepublished online as Blood First Edition Paper, October 31, 2002; DOI 10.1182/blood-2002-06-1837.

Supported by Cancerfonden.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Butcher
EC
Picker
LJ
Lymphocyte homing and homeostasis.
Science.
272
1996
60
66
2
MacLennan
IC
Germinal centers.
Annu Rev Immunol.
12
1994
117
139
3
Moser
B
Loetscher
P
Lymphocyte traffic control by chemokines.
Nat Immunol.
2
2001
123
128
4
Lesley
J
Hyman
R
Kincade
PW
CD44 and its interaction with extracellular matrix.
Adv Immunol.
54
1993
271
335
5
Rafi
A
Nagarkatti
M
Nagarkatti
PS
Hyaluronate-CD44 interactions can induce murine B-cell activation.
Blood.
89
1997
2901
2908
6
Foger
N
Marhaba
R
Zoller
M
CD44 supports T cell proliferation and apoptosis by apposition of protein kinases.
Eur J Immunol.
30
2000
2888
2899
7
Chen
D
McKallip
RJ
Zeytun
A
et al
CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death.
J Immunol.
166
2001
5889
5897
8
Naor
D
Sionov
RV
Ish-Shalom
D
CD44: structure, function, and association with the malignant process.
Adv Cancer Res.
71
1997
241
319
9
Guo
Y
Wu
Y
Shinde
S
Sy
MS
Aruffo
A
Liu
Y
Identification of a costimulatory molecule rapidly induced by CD40L as CD44H.
J Exp Med.
184
1996
955
961
10
Ingvarsson
S
Dahlenborg
K
Carlsson
R
Borrebaeck
CA
Co-ligation of CD44 on naive human tonsillar B cells induces progression towards a germinal center phenotype.
Int Immunol.
11
1999
739
744
11
Camp
RL
Kraus
TA
Birkeland
ML
Pure
E
High levels of CD44 expression distinguish virgin from antigen-primed B cells.
J Exp Med.
173
1991
763
766
12
Arch
R
Wirth
K
Hofmann
M
et al
Participation in normal immune responses of a metastasis-inducing splice variant of CD44.
Science.
257
1992
682
685
13
Kremmidiotis
G
Zola
H
Changes in CD44 expression during B cell differentiation in the human tonsil.
Cell Immunol.
161
1995
147
157
14
Feuillard
J
Taylor
D
Casamayor-Palleja
M
Johnson
GD
MacLennan
IC
Isolation and characteristics of tonsil centroblasts with reference to Ig class switching.
Int Immunol.
7
1995
121
130
15
Dahlenborg
K
Pound
JD
Gordon
J
Borrebaeck
CA
Carlsson
R
Terminal differentiation of human germinal center B cells in vitro.
Cell Immunol.
175
1997
141
149
16
Stott
DI
Hiepe
F
Hummel
M
Steinhauser
G
Berek
C
Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome.
J Clin Invest.
102
1998
938
946
17
Kim
HJ
Berek
C
B cells in rheumatoid arthritis.
Arthritis Res.
2
2000
126
131
18
Lindhout
E
van Eijk
M
van Pel
M
Lindeman
J
Dinant
HJ
de Groot
C
Fibroblast-like synoviocytes from rheumatoid arthritis patients have intrinsic properties of follicular dendritic cells.
J Immunol.
162
1999
5949
5956
19
Aarvak
T
Natvig
JB
Cell-cell interactions in synovitis: antigen presenting cells and T cell interaction in rheumatoid arthritis.
Arthritis Res.
3
2001
13
17
20
Haynes
BF
Hale
LP
Patton
KL
Martin
ME
McCallum
RM
Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis.
Arthritis Rheum.
34
1991
1434
1443
21
Mikecz
K
Dennis
K
Shi
M
Kim
JH
Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis.
Arthritis Rheum.
42
1999
659
668
22
Schadt
EE
Li
C
Su
C
Wong
WH
Analyzing high-density oligonucleotide gene expression array data.
J Cell Biochem.
80
2000
192
202
23
Li
C
Wong
WH
Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.
Proc Natl Acad Sci U S A.
98
2001
31
36
24
Ek
S
Hogerkorp
CM
Dictor
M
Ehinger
M
Borrebaeck
CA
Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells.
Cancer Res.
62
2002
4398
4405
25
Banchereau
J
de Paoli
P
Valle
A
Garcia
E
Rousset
F
Long-term human B cell lines dependent on interleukin-4 and antibody to CD40.
Science.
251
1991
70
72
26
Bowman
EP
Campbell
JJ
Druey
KM
Scheschonka
A
Kehrl
JH
Butcher
EC
Regulation of chemotactic and proadhesive responses to chemoattractant receptors by RGS (regulator of G-protein signaling) family members.
J Biol Chem.
273
1998
28040
28048
27
Reif
K
Cyster
JG
RGS molecule expression in murine B lymphocytes and ability to down-regulate chemotaxis to lymphoid chemokines.
J Immunol.
164
2000
4720
4729
28
Elenkov
IJ
Wilder
RL
Chrousos
GP
Vizi
ES
The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system.
Pharmacol Rev.
52
2000
595
638
29
Waguri-Nagaya
Y
Otsuka
T
Sugimura
I
et al
Synovial inflammation and hyperplasia induced by gliostatin/platelet-derived endothelial cell growth factor in rabbit knees.
Rheumatol Int.
20
2000
13
19
30
Tilg
H
Dinarello
CA
Mier
JW
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators.
Immunol Today.
18
1997
428
432
31
Labow
M
Shuster
D
Zetterstrom
M
et al
Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice.
J Immunol.
159
1997
2452
2461
32
Horai
R
Asano
M
Sudo
K
et al
Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion.
J Exp Med.
187
1998
1463
1475
33
Zubiaga
AM
Munoz
E
Huber
BT
Production of IL-1 α by activated Th type 2 cells. Its role as an autocrine growth factor.
J Immunol.
146
1991
3849
3856
34
Huber
M
Beuscher
HU
Rohwer
P
Kurrle
R
Rollinghoff
M
Lohoff
M
Costimulation via TCR and IL-1 receptor reveals a novel IL-1α-mediated autocrine pathway of Th2 cell proliferation.
J Immunol.
160
1998
4242
4247
35
Teder
P
Vandivier
RW
Jiang
D
et al
Resolution of lung inflammation by CD44.
Science.
296
2002
155
158
36
Liu
YJ
Arpin
C
de Bouteiller
O
et al
Sequential triggering of apoptosis, somatic mutation and isotype switch during germinal center development.
Semin Immunol.
8
1996
169
177
37
Koehne
P
Schaper
C
Graf
K
Kunkel
G
Neutral endopeptidase 24.11: its physiologic and possibly pathophysiologic role in inflammation with special effect on respiratory inflammation.
Allergy.
53
1998
1023
1042
38
Onel
KB
Tucek-Szabo
CL
Ashany
D
Lacy
E
Nikolic-Zugic
J
Elkon
KB
Expression and function of the murine CD95/FasR/APO-1 receptor in relation to B cell ontogeny.
Eur J Immunol.
25
1995
2940
2947
39
Ohshima
S
Saeki
Y
Mima
T
et al
Interleukin 6 plays a key role in the development of antigen-induced arthritis.
Proc Natl Acad Sci U S A.
95
1998
8222
8226
40
La Flamme
AC
Pearce
EJ
The absence of IL-6 does not affect Th2 cell development in vivo, but does lead to impaired proliferation, IL-2 receptor expression, and B cell responses.
J Immunol.
162
1999
5829
5837
41
Baccam
M
Bishop
GA
Membrane-bound CD154, but not CD40-specific antibody, mediates NF-κB-independent IL-6 production in B cells.
Eur J Immunol.
29
1999
3855
3866
42
Fujii
K
Tanaka
Y
Hubscher
S
Saito
K
Ota
T
Eto
S
Crosslinking of CD44 on rheumatoid synovial cells augment interleukin 6 production.
Lab Invest.
79
1999
1439
1446
43
Sconocchia
G
Campagnano
L
Adorno
D
et al
CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production.
Blood.
97
2001
3621
3627
44
Khaldoyanidi
S
Karakhanova
S
Sleeman
J
Herrlich
P
Ponta
H
CD44 variant-specific antibodies trigger hemopoiesis by selective release of cytokines from bone marrow macrophages.
Blood.
99
2002
3955
3961
45
Webb
DS
Shimizu
Y
Van Seventer
GA
Shaw
S
Gerrard
TL
LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release.
Science.
249
1990
1295
1297
46
Noble
PW
Lake
FR
Henson
PM
Riches
DW
Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor-α-dependent mechanism in murine macrophages.
J Clin Invest.
91
1993
2368
2377
47
McArthur
JG
Raulet
DH
CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4.
J Exp Med.
178
1993
1645
1653
48
Esmon
CT
Role of coagulation inhibitors in inflammation.
Thromb Haemost.
86
2001
51
56
49
Kaneider
NC
Reinisch
CM
Dunzendorfer
S
Romisch
J
Wiederman
CJ
Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes.
J Cell Sci.
115
2002
227
236
50
Oelschlager
C
Romisch
J
Staubitz
A
et al
Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells.
Blood.
99
2002
4015
4020
51
Sternberg
EM
Neuroendocrine regulation of autoimmune/inflammatory disease.
J Endocrinol.
169
2001
429
435
52
Kohm
AP
Sanders
VM
Norepinephrine: a messenger from the brain to the immune system.
Immunol Today.
21
2000
539
542
53
Kohm
AP
Sanders
VM
Suppression of antigen-specific Th2 cell-dependent IgM and IgG1 production following norepinephrine depletion in vivo.
J Immunol.
162
1999
5299
5308
54
Kasprowicz
DJ
Kohm
AP
Berton
MT
Chruscinski
AJ
Sharpe
A
Sanders
VM
Stimulation of the B cell receptor, CD86 (B7–2), and the β 2-adrenergic receptor intrinsically modulates the level of IgG1 and IgE produced per B cell.
J Immunol.
165
2000
680
690
55
Baerwald
CG
Burmester
GR
Krause
A
Interactions of autonomic nervous, neuroendocrine, and immune systems in rheumatoid arthritis.
Rheum Dis Clin North Am.
26
2000
841
857
56
Fedyk
ER
Adawi
A
Looney
RJ
Phipps
RP
Regulation of IgE and cytokine production by cAMP: implications for extrinsic asthma.
Clin Immunol Immunopathol.
81
1996
101
113
57
Nagao
F
Suzui
M
Takeda
K
Yagita
H
Okumura
K
Mobilization of NK cells by exercise: downmodulation of adhesion molecules on NK cells by catecholamines.
Am J Physiol Regul Integr Comp Physiol.
279
2000
R1251
R1256

Author notes

Carl A. K. Borrebaeck, Department of Immunotechnology, Lund University, PO Box 7031, SE-220 07 Lund, Sweden; e-mail: carl.borrebaeck@immun.lth.se.

Sign in via your Institution